Could CBD help curb opioid cravings? new study investigates
NCT ID NCT06206291
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether cannabidiol (CBD) can reduce craving and anxiety in 76 adults with opioid use disorder who were already on opioid agonist therapy (like methadone). Participants took CBD or a placebo twice daily for 4 weeks, then all took a higher dose of CBD for another 4 weeks. The study measured changes in craving, anxiety, and drug use through urine tests and self-reports.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cannabidiol (CBD)
What this could lead to
If it works, CBD could become a safe, non-addictive add-on treatment to help people with opioid use disorder manage cravings and stay in recovery.
What could go wrong
This is a small, early-phase trial (76 people) with no placebo comparison for the full 8 weeks. Results may not apply to everyone, and CBD's effects on opioid craving are still uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States